Desarrollo de nuevos fármacos antivirales frente al virus del Ébola
Loading...
Download
Official URL
Full text at PDC
Publication date
2024
Defense date
04/04/2024
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citation
Abstract
La enfermedad ocasionada por el virus del Ébola (EBOV) provoca fiebres hemorrágicas en humanos y tiene una tasa de mortalidad de hasta el 60%. A pesar de que existen vacunas preventivas aprobadas y dos tratamientos farmacológicos basados en anticuerpos monoclonales para combatir la enfermedad, siguen apareciendo continuos brotes de EBOV en los países donde la enfermedad es endémica, principalmente en África Occidental. Las condiciones de almacenamiento y transporte, así como los costes de producción, dificultan la llegada de las vacunas y los tratamientos a su población objetivo. Es por ello que, en la presente tesis doctoral titulada: “Desarrollo de nuevos fármacos antivirales frente al virus del Ébola”, se proponen nuevas aproximaciones para el tratamiento de esta enfermedad basadas en el empleo de moléculas pequeñas, tratando de solventar así los problemas que presentan los fármacos aprobados...
Ebola virus disease (EVD) causes haemorrhagic fevers in humans and has a mortality rate of 60%. Despite the availability of approved preventive vaccines and two monoclonal antibody-based drug treatments to combat the disease, outbreaks of EBOV continue to occur in countries where the disease is endemic, mainly in West Africa. Storage and transport conditions, as well as production costs, make it difficult for vaccines and treatments to reach their target population. In this thesis entitled: "Development of new antiviral drugs against Ebola virus", new approaches for the treatment of this disease based on the use of small molecules are proposed, thus trying to solve the problems presented by the approved drugs...
Ebola virus disease (EVD) causes haemorrhagic fevers in humans and has a mortality rate of 60%. Despite the availability of approved preventive vaccines and two monoclonal antibody-based drug treatments to combat the disease, outbreaks of EBOV continue to occur in countries where the disease is endemic, mainly in West Africa. Storage and transport conditions, as well as production costs, make it difficult for vaccines and treatments to reach their target population. In this thesis entitled: "Development of new antiviral drugs against Ebola virus", new approaches for the treatment of this disease based on the use of small molecules are proposed, thus trying to solve the problems presented by the approved drugs...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Ciencias Químicas, leída el 04-04-2024